[go: up one dir, main page]

NO20090368L - Cyanocobalamin lav viskositets vandige formuleringer for intranasal avlevering - Google Patents

Cyanocobalamin lav viskositets vandige formuleringer for intranasal avlevering

Info

Publication number
NO20090368L
NO20090368L NO20090368A NO20090368A NO20090368L NO 20090368 L NO20090368 L NO 20090368L NO 20090368 A NO20090368 A NO 20090368A NO 20090368 A NO20090368 A NO 20090368A NO 20090368 L NO20090368 L NO 20090368L
Authority
NO
Norway
Prior art keywords
cyanocobalamin
solution
csf
low viscosity
aqueous formulations
Prior art date
Application number
NO20090368A
Other languages
English (en)
Inventor
Steven Quay
Zenaida O Go
Peter C Aprile
Antony P Sileno
Original Assignee
Qol Medical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qol Medical Llc filed Critical Qol Medical Llc
Publication of NO20090368L publication Critical patent/NO20090368L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En stabil farmasøytisk vannholdig løsning av cyanokobalamin omfattende cyanokobalamin og vann hvor nevnte løsning av cyanokobalamin er egnet for intranasal administrasjon, har en viskositet mindre enn omkring 1000 cPs, og gir en biotilgjengelighet av cyanokobalamin når administrert intranasalt på minst omkring 5% relativ til en intramuskulær injeksjon av cyanokobalamin. Den foreliggende oppfinnelsen er også rettet mot en fremgangsmåte for å heve vitamin B12 nivåene i den cerebrale spinalvæsken (CSF) omfattende å administrere intranasalt en tilstrekkelig mengde av en cyanokobalamin løsning for å øke det gjennomsnittlige forholdet av vitamin Bl2 i CSF i forhold til det i blodserumet (Bl2 CSF/B12 serum x 100) til minst omkring 1,1, omfattende intranasalt å administrere en vannholdig løsning av cyanokobalamin, hvor nevnte løsning av cyanokobalamin har en biotilgjengelighet på minst 5% relativ til en intramuskulær injeksjon av et cyanokobalamin.
NO20090368A 2006-06-23 2009-01-23 Cyanocobalamin lav viskositets vandige formuleringer for intranasal avlevering NO20090368L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/024685 WO2007149098A1 (en) 2006-06-23 2006-06-23 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

Publications (1)

Publication Number Publication Date
NO20090368L true NO20090368L (no) 2009-03-23

Family

ID=38833714

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090368A NO20090368L (no) 2006-06-23 2009-01-23 Cyanocobalamin lav viskositets vandige formuleringer for intranasal avlevering

Country Status (10)

Country Link
EP (1) EP2035441A4 (no)
JP (1) JP5769924B2 (no)
KR (3) KR20140101010A (no)
CN (1) CN101600729A (no)
AU (1) AU2006344733B2 (no)
CA (1) CA2656823C (no)
IL (2) IL196038A (no)
NO (1) NO20090368L (no)
WO (1) WO2007149098A1 (no)
ZA (1) ZA200900191B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632430B1 (en) * 2010-10-29 2018-06-06 Troikaa Pharmaceuticals Ltd Nasal compositions of vitamin b12
CA3055094A1 (en) * 2017-03-02 2018-09-07 Dutch Renewable Energy B.V. Intranasal administration of physiologically active substances
WO2022026762A1 (en) * 2020-07-29 2022-02-03 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient
WO2025003468A1 (en) 2023-06-30 2025-01-02 Dutch Renewable Energy B.V. Vitamin b12 formulation for intranasal administration

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724231A (en) * 1985-04-16 1988-02-09 Nastech Pharmaceutical, Inc. Nasel compositions containing vitamin B12
JPS62500788A (ja) * 1985-04-16 1987-04-02 ナステツク　フア−マス−テイカル　カンパニ−　インコ−ポレイテツド ビタミンｂ↓１↓２の経鼻噴霧用エアロゾ−ル組成物
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US4959176A (en) * 1988-04-29 1990-09-25 Beckman Instruments, Inc. High resolution non corrosive amino acid analysis buffer solutions
US5227311A (en) * 1988-10-11 1993-07-13 Abbott Laboratories Intrinsic factor to determine B12
BE1007839A6 (nl) * 1993-12-20 1995-10-31 Merkus Franciscus W H M Prof Farmaceutische compositie voor de nasale toediening van hydroxocobalamine.
US6406730B1 (en) * 1998-12-01 2002-06-18 Carl E. Banyard Process for producing low acid food products
FR2787029A1 (fr) * 1998-12-09 2000-06-16 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de vitamine b12 pour la delivrance d'agents actifs au systeme nerveux central
WO2002024165A2 (en) * 2000-09-20 2002-03-28 Nycomed Pharma As Preparation of vitamin emulsions and concentrates thereof
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
DE10300719A1 (de) * 2003-01-11 2004-07-22 Basf Ag Verbessertes Verfahren zur Herstellung von Vitamin B12
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法

Also Published As

Publication number Publication date
KR20170098977A (ko) 2017-08-30
CA2656823C (en) 2015-02-03
CA2656823A1 (en) 2007-12-27
ZA200900191B (en) 2012-09-26
IL196038A0 (en) 2009-09-01
IL248447B (en) 2021-10-31
IL248447A0 (en) 2016-11-30
CN101600729A (zh) 2009-12-09
IL196038A (en) 2016-10-31
KR20090074722A (ko) 2009-07-07
AU2006344733B2 (en) 2014-02-27
JP2009541312A (ja) 2009-11-26
JP5769924B2 (ja) 2015-08-26
AU2006344733A1 (en) 2007-12-27
EP2035441A4 (en) 2013-01-16
EP2035441A1 (en) 2009-03-18
KR20140101010A (ko) 2014-08-18
WO2007149098A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
UA92470C2 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
WO2009105432A3 (en) Devices and methods for delivery of a therapeutic agent through a pneumostoma
EP3542792A1 (en) Controlled release 25-hydroxyvitamin d
NO20054711L (no) Fremgangsmater og farmasoytiske blandinger for palitelig oppnaelse av akseptable serum-testosteronnivaer
WO2004105702A3 (en) Foamable pharmaceutical compositions and methods for treating a disorder
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
MX343867B (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
NO20090368L (no) Cyanocobalamin lav viskositets vandige formuleringer for intranasal avlevering
ATE507818T1 (de) Orale verabreichung eines calcitonins
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
MY144021A (en) Pharmaceutical delivery system
UA102187C2 (ru) Фармацевтическая композиция для пероральной доставки дииндолилметана
JP2009504767A (ja) ビタミンｂ１２鼻用スプレーおよび使用方法
ATE475484T1 (de) Dosiervorrichtung
DK1883387T3 (da) Beholder til flydende medikamenter, der skal administreres
WO2005020959A3 (en) Novel drug compositions and dosage forms of topiramate
NO20065453L (no) Fenoksyalkykarboksylsyrederivater i behandlingen av inflammatoriske sykdommer.
WO2009051217A1 (ja) フェンタニル含有経皮吸収製剤
WO2002070014A8 (en) Compositions comprising an o/w emulsion containing conjugated linoleic acid
WO2009061445A3 (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ENDO PHARMACEUTICALS INC, US

FC2A Withdrawal, rejection or dismissal of laid open patent application